Adding thanks rather than a view. I do not have a view worth the space.
Managing an unplanned gap in supply posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
I would keep managing an unplanned gap and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Picking up post #30: that is the part I would want checked first.
Device availability and compound availability are separate supply chains and the device is frequently the constraint.
Having read the whole managing an unplanned gap thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Regional differences during a shortage are large, and a supply position in one country says nothing about another.
I have written this out at length because the short version keeps being misread.
Managing an unplanned gap is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Narrowing post #38, because the general version has more than one answer.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Genuinely open to being wrong about this one.
This is the first time the answer has come with its own limits attached. Appreciated.
Coming back to post #37, because the follow-up matters more than the original answer.
Small correction to my own earlier position on managing an unplanned gap. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Collapsed as off-topic by two members at trust level 3 or above
Post #41 is right about the mechanism and I think understates the practical bit.
Worth separating managing an unplanned gap as a question about the compound from managing an unplanned gap as a question about the documentation. They get answered by different people and only one of them is answerable here.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
That is a description of practice, not a recommendation of it.
I had written a reply contradicting post #41 and deleted it. Here is what survived.
Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration discussion with a clinician.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
Not the answer, but possibly the question that gets there.
Where I have landed on managing an unplanned gap, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
Bookmarking this. I will come back when I have something worth adding.
Communication from suppliers: a supplier having supply problems usually communicates them. If a supplier goes silent, that is itself information.
Somebody will have a better source than mine, and I hope they post it.
Collapsed as off-topic by two members at trust level 3 or above
Reading rather than answering, but this is the post I would point somebody at.
Managing an unplanned gap came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
I have said this before in a thread nobody could find, so it is worth repeating.
Post #52 is the version of this I will quote in future. One addition.
Device availability and compound availability are separate supply chains and the device is frequently the constraint.
Where I part company with post #54, and it is a narrow parting.
The arithmetic on managing an unplanned gap is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
A note on how managing an unplanned gap gets discussed rather than on managing an unplanned gap itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Regional differences during a shortage are large, and a supply position in one country says nothing about another.
I would hold that lightly until someone with a larger sample weighs in.
That matches what I have seen, for whatever a single anecdote is worth.